Empowering biotherapeutic production - Used in multiple, successful IND filings - Licensed to >70 companies - Recognized in the industry and by regulators for high yield manufacturing
Drive efficiencies during development and production
Freedom to choose - any media, vector or CRO/CMO
Freedom to operate – no patent or IP risks
Maintain profitability throughout product life cycle - royalty-free licensing
Gene editing CHO cell services
Improve your CHO cell performance
Meet demands for cost-effective biomanufacturing
Ensure a clear IP position with freedom to operate
News highlights
CHOSOURCE™ platform supports development of immunotherapy for autoimmune diseases
CHOSOURCE™ platform offered for COVID-19-related therapeutics and diagnostics
Multi-product use license of GS knockout CHO K1 cell line granted to NGM Bio
Glenmark adopts CHO cell line into biomanufacturing process